Chemomab Therapeutics Ltd. (CMMB)

Market Cap	12.16M
Revenue (ttm)	n/a
Net Income (ttm)	-19.34M
Shares Out	14.22M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	13.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,907
Open	0.866
Previous Close	0.870
Day's Range	0.827 - 0.880
52-Week Range	0.420 - 1.890
Beta	-0.03
Analysts	Strong Buy
Price Target	5.67 (+574.2%)
Earnings Date	May 9, 2024

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: CMMB

Analyst Forecast

According to 3 analysts, the average rating for CMMB stock is "Strong Buy." The 12-month stock price forecast is $5.67, which is an increase of 574.20% from the latest price.

Price Target

$5.67

(574.20% upside)

Analyst Consensus: Strong Buy